UNSPSC 51333401: Alpertine

This classification denotes an antipsychotic agent with the molecular formula C25H31N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KYT38QTB4K, chemically known as 1h-indole-2-carboxylic acid, 5,6-dimethoxy-3-(2-(4-phenyl-1-piperazinyl)ethyl)-,ethyl ester but generally known as alpertine, which bears US NIH Compound Identifier 166547. European Medicines Agency schedules Alpertine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05362MIG.

UNSPSC 51333401 Alpertine (Commodity) describes pharmaceutical products and naloxone-based overdose reversal systems that state and local governments procure for community health, emergency response, and pharmacy benefit programs. State and local buyers use this code for procurement of naloxone units, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products supplied through authorized wholesalers and direct-to-manufacturer channels. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida has solicited annual procurement of 1,900 naloxone units and 800 safe drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission has issued a Request for Information to evaluate direct-to-manufacturer prescription fulfillment capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has issued an RFP to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon.

Recent activity spans Florida, Texas, and Minnesota through MMCAP's multistate vehicle. Seminole County's IFB 60459723LAS, posted June 30, 2026 with response due July 26, 2023, seeks quarterly deliveries of naloxone and drug deactivation systems with a two-year initial term and one-year renewal option; the contract is potentially FEMA-funded and includes a three-month probationary period. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, gathers vendor capabilities for establishing direct contracts with manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels, using negotiated net pricing models. MMCAP's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, establishes contracts for generic pharmaceuticals and OTC products effective July 1, 2026, distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative fee compliance, EDI capability, and administrative fee agreement. All vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.